CHAPEL HILL, N.C., June 10, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that research findings for the company’s lead product, solithromycin, will be presented at the American Society of Microbiology (ASM) Microbe 2016 Conference, taking place in Boston on June 16-20, 2016.
Presentation details are as follows:
Title: Microbiological Diagnoses from a Recent Community-acquired Bacterial Pneumonia (CABP) Trial – Solitaire-IV
Authors: A. Sheets, K. Keedy, B. Jamieson, D. Oldach, P. Fernandes
Date/Time: Saturday, June 18 from 12:45 – 2:45 p.m. ET
Session: Macrolides, Oxazolidones, and Related Compounds I
Location: Boston Convention and Exhibition Center, Halls A and B
An abstract is available here.
Title: Solithromycin, a Novel Fluoroketolide, In Vitro Antibacterial Activity against Anaerobes Isolated in Japan
Authors: Y. Yamagishi, Y. Matsukawa, H. Suematsu, H. Mikamo
Date/Time: Sunday, June 19 from 12:30 – 2:30 p.m. ET
Session: Macrolides, Oxazolidones, and Related Compounds II
Location: Boston Convention and Exhibition Center, Halls A and B
An abstract is available here.
About Solithromycin
Solithromycin is a highly potent next-generation macrolide, the first fluoroketolide, which has potent activity against most macrolide-resistant strains. In vitro and in vivo studies have shown potent activity against S. pneumoniae as well as an extended spectrum of activity against CA-MRSA, streptococci, haemophilus, enterococci, Mycobacterium avium and in animal models of malaria. It is also active against atypical bacteria, such as legionella, chlamydia, mycoplasma and ureaplasma, and against gonococci and other organisms that cause genitourinary tract infections. It is 8-16 times more potent than azithromycin against many bacteria and is active against azithromycin-resistant strains. Solithromycin's activity against resistant strains is driven by its ability to interact with three sites on the bacterial ribosome, compared to one for current macrolides. The binding to bacterial ribosomes and interaction with three ribosomal sites is expected to limit the development of bacterial resistance to solithromycin.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and new drug applications for the intravenous and oral capsule formulations have been submitted to the FDA. Solithromycin is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is being tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.